Small Cell Bladder Cancer Response to Second-line and Beyond Checkpoint Inhibitor Therapy: Retrospective Experience

Jean Hoffman-Censits; Woonyoung Choi; Trinity J. Bivalacqua; Philip Pierorazio; Max Kates; Kara Lombardo; Vamsi Parini; David McConkey; Edouard J. Trabulsi; Noah Hahn; Andres Matoso

doi:10.1016/j.clgc.2020.10.009

Small Cell Bladder Cancer Response to Second-line and Beyond Checkpoint Inhibitor Therapy: Retrospective Experience

Jean Hoffman-Censits, Woonyoung Choi, Trinity J. Bivalacqua, Philip Pierorazio, Max Kates, Kara Lombardo, Vamsi Parini, David McConkey, Edouard J. Trabulsi, Noah Hahn, Andres Matoso

School of Medicine

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	176-181
Number of pages	6
Journal	Clinical Genitourinary Cancer
Volume	19
Issue number	2
DOIs	https://doi.org/10.1016/j.clgc.2020.10.009
State	Published - Apr 2021

Keywords

Immunotherapy
Neuroendocrine cancer
Platinum refractory cancer
Upper tract
Variant histology

ASJC Scopus subject areas

Urology
Oncology

Access to Document

10.1016/j.clgc.2020.10.009

Cite this

Hoffman-Censits, J., Choi, W., Bivalacqua, T. J., Pierorazio, P., Kates, M., Lombardo, K., Parini, V., McConkey, D., Trabulsi, E. J., Hahn, N., & Matoso, A. (2021). Small Cell Bladder Cancer Response to Second-line and Beyond Checkpoint Inhibitor Therapy: Retrospective Experience. Clinical Genitourinary Cancer, 19(2), 176-181. https://doi.org/10.1016/j.clgc.2020.10.009

@article{f4424f1eec244440a7c16b9215408022,

title = "Small Cell Bladder Cancer Response to Second-line and Beyond Checkpoint Inhibitor Therapy: Retrospective Experience",

keywords = "Immunotherapy, Neuroendocrine cancer, Platinum refractory cancer, Upper tract, Variant histology",

author = "Jean Hoffman-Censits and Woonyoung Choi and Bivalacqua, {Trinity J.} and Philip Pierorazio and Max Kates and Kara Lombardo and Vamsi Parini and David McConkey and Trabulsi, {Edouard J.} and Noah Hahn and Andres Matoso",

note = "Funding Information: Dr Hoffman-Censits reports medical writing services from Genentech, Advisory board for Seattle Genetics, and consultant services for Astra Zeneca. Dr Bivalacqua reports advisory boards for Genesis Biotech and Janssen; and consultant for Feregene, BiogenesisPierorazio: Urogen, and Olympus. Dr Kates reports advisory boards for Genesis Biotech and Janssen; and consultant for Feregene and Pacific Edge. Dr McKonkey reports honoraria from Janssen, H3 Biomedicine, and Rainier; and grant funding from Astra Zeneca, Bioclin, and Rainier Pharma. Dr Trabulsi reports consultant for Pfizer, Astellas, Janssen, and GenomeDx. Dr Hahn reports consultant for Genentech, Merck, Seattle Genetics, Incyte, Janssen, Pieris, Boehringer Ingelheim, Glaxo Smith Kline, Ferring, and Pfizer; and research support from Genetech, Merck, BMS, Seattle genetics, Incyte, Inovio, Janssen, Pieris, Astra Zeneca, and HTG Molecular. The remaining authors have stated that they have no conflicts of interest.",

year = "2021",

month = apr,

doi = "10.1016/j.clgc.2020.10.009",

language = "English (US)",

volume = "19",

pages = "176--181",

journal = "Clinical Genitourinary Cancer",

issn = "1558-7673",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Small Cell Bladder Cancer Response to Second-line and Beyond Checkpoint Inhibitor Therapy

T2 - Retrospective Experience

AU - Hoffman-Censits, Jean

AU - Choi, Woonyoung

AU - Bivalacqua, Trinity J.

AU - Pierorazio, Philip

AU - Kates, Max

AU - Lombardo, Kara

AU - Parini, Vamsi

AU - McConkey, David

AU - Trabulsi, Edouard J.

AU - Hahn, Noah

AU - Matoso, Andres

N1 - Funding Information: Dr Hoffman-Censits reports medical writing services from Genentech, Advisory board for Seattle Genetics, and consultant services for Astra Zeneca. Dr Bivalacqua reports advisory boards for Genesis Biotech and Janssen; and consultant for Feregene, BiogenesisPierorazio: Urogen, and Olympus. Dr Kates reports advisory boards for Genesis Biotech and Janssen; and consultant for Feregene and Pacific Edge. Dr McKonkey reports honoraria from Janssen, H3 Biomedicine, and Rainier; and grant funding from Astra Zeneca, Bioclin, and Rainier Pharma. Dr Trabulsi reports consultant for Pfizer, Astellas, Janssen, and GenomeDx. Dr Hahn reports consultant for Genentech, Merck, Seattle Genetics, Incyte, Janssen, Pieris, Boehringer Ingelheim, Glaxo Smith Kline, Ferring, and Pfizer; and research support from Genetech, Merck, BMS, Seattle genetics, Incyte, Inovio, Janssen, Pieris, Astra Zeneca, and HTG Molecular. The remaining authors have stated that they have no conflicts of interest.

PY - 2021/4

Y1 - 2021/4

KW - Immunotherapy

KW - Neuroendocrine cancer

KW - Platinum refractory cancer

KW - Upper tract

KW - Variant histology

UR - http://www.scopus.com/inward/record.url?scp=85098632520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85098632520&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2020.10.009

DO - 10.1016/j.clgc.2020.10.009

M3 - Article

C2 - 33358150

AN - SCOPUS:85098632520

SN - 1558-7673

VL - 19

SP - 176

EP - 181

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

IS - 2

ER -

Small Cell Bladder Cancer Response to Second-line and Beyond Checkpoint Inhibitor Therapy: Retrospective Experience

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this